Business
Kymera Therapeutics Announces First Quarter 2022 Financial Results and Provides a Business Update
IRAK4 degrader KT-474 Phase 1 patient cohort amended to extend dosing from 14 to 28 days, enabling inclusion of exploratory clinical efficacy endpoints and
About this update from Kymera Therapeutics, Inc.
[{"type":"text","content":"IRAK4 degrader KT-474 Phase 1 patient cohort amended to extend dosing from 14 to 28 days, enabling inclusion of exploratory clinical efficacy endpoints and extended safety monitoring Clinical trials initiated for STAT3 (KT-333) and IRAKIMiD (KT-413) oncology programs Pre-clinical data presented at AACR on first-in-class MDM2 degrader, KT-253, highlighting the potential benefit of degradation over inhibition and broader clinical opportunities; IND filing planned for 2H22 March 31, 2022 cash balance of approximately $523 million, providing cash runway into 2025 Company to hold quarterly results call at 8am EST (833-740-0921 or 409-937-8885, ID #2984916) WATERTOWN, Mass., May 03, 2022 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today reported business highlights and financial results for the first quarter ended March 31, 2022. “Kymera has made continued progress in the first quarter against our goals to build a fully integrated degrader medicines company,” said Nello Mainofi, PhD, Co-Founder, President and CEO. “With three active clinical programs, 2022 promises to be a year rich in data and milestones that build upon our prior scientific achievements. Of note, we anticipate sharing initial safety and proof-of-mechanism data for our two oncology programs, KT-413 and KT-333, and filing an IND for our MDM2 program, KT-253, in the second half of 2022. Additionally, we have finalized the dose selection and amended the design of the KT-474 Phase 1 patient cohort to include 28 days of dosing, which is now expected to deliver additional key de-risking data in 2H22. With a robust pre-clinical pipeline complementing our clinical stage programs, and a cash runway into 2025, we remain well-positioned to deliver at least one new clinical program per year, thus broadening the potential clinical and eventual commercial impact of our pipeline.” Business Highlights and Recent Developments IRAK4 Degrader Program (KT-474) Background. KT-474 is designed as a potent, highly selective, orally bioavailable IRAK4 degrader, in development for the treatment of IL-1R/TLR-driven autoimmune and autoinflammatory diseases with high unmet medical needs. In 2021, Kymera completed dose escalation in the sin...